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Halper-Stromberg et al. use a humanized mouse model to demonstrate that broadly neutralizing
antibodies, when administered with a combination of HIV latency activators, can reduce persistent
HIV reservoirs, as measured by plasma virus rebound. Their results support the use of broadly
neutralizing antibodies in HIV-reservoir-purging strategies.Human immunodeficiency virus (HIV)
infection causes devastating damage to
the host immune system, culminating in
the development of acquired immunode-
ficiency syndrome (AIDS). Antiretroviral
therapy (ART) can inhibit HIV replication,
suppress HIV plasma viral loads to
undetectable levels, and prevent disease
progression. Yet ART alone is not cura-
tive. Instead, HIV persists in rare cellular
reservoirs within treated individuals,
allowing virus to rapidly re-emerge if
therapy is stopped (Marsden and Zack,
2013). Several cellular reservoirs might
contribute to the maintenance of HIV
during ART, but the largest and best
understood consists of latently infected
memory CD4+ T cells (Chun et al., 1997;
Finzi et al., 1999; Wong et al., 1997).
These long-lived cells harbor integrated,
nonexpressing HIV proviruses within
their chromosomes, and in this latent
state the virus is not susceptible to
immune effector mechanisms or antire-
troviral drugs. However, if the host cell
becomes stimulated, the latent virus can
be awakened to produce new infectious
virions. Latently infected cells can persist
for decades in infected individuals even
during effective ART (Finzi et al., 1999).
Therefore, if an HIV cure is to be achieved,
methods will have to be developed to
eliminate the latent reservoir. In this issue
of Cell, Halper-Stromberg et al. provide a
proof of concept that it is possible to
target the HIV reservoir (Halper-Strom-
berg et al., 2014).
A key requirement for testing methods
intended to eliminate persistent HIV reser-
voirs is the availability of relevant smallanimal models for HIV latency. Human-
ized mice have served as models for
HIV infection and pathogenesis for more
than 25 years (Namikawa et al., 1988).
In these models, introduction of human
cells into immunodeficient mice allows
the generation of a human immune
system, complete with CD4+ cells sus-
ceptible to infection with HIV (Figure 1).
Humanized mouse models have con-
tinuously been refined to provide more
comprehensive and authentic immune
reconstitution. Using these advanced
approaches, it is now possible to infect
mice with HIV, treat them with antiretro-
viral drugs, and show that HIV latency is
formed in multiple tissues, providing a
tractable system for testing HIV reservoir
purging strategies (Choudhary et al.,
2012; Denton et al., 2012; Marsden
et al., 2012).
Utilizing a humanized mouse model,
Halper-Stromberg et al. show that broadly
neutralizing anti-HIV antibodies (bNAbs)
can be used to influence the formation
and maintenance of persistent HIV reser-
voirs (Halper-Stromberg et al., 2014).
These bNAbs bind to the viral envelope
glycoprotein spikes present on the sur-
face of the virus particle and infected cells
and are capable of neutralizing a diverse
range of HIV strains. The authors first
demonstrate that bNAbs can be used for
postexposure prophylaxis if administered
soon after primary infection. They show
that, when a mixture of three bNAbs is
introduced in multiple doses beginning
at day 4 post infection, the majority of
recipient mice do not show a subsequent
rebound in plasma viremia. This is impor-Cell 15tant because HIV has likely already gone
through several replication cycles by this
time point, and treatment with ART at
this stage is not usually sufficient to pre-
vent the establishment of a persistent
infection. The improved efficacy of bNAbs
in this context is likely because antibodies
function very differently from ART. Anti-
bodies interact with the broader immune
response in a variety of ways, including
through antibody-dependent cell-medi-
ated cytotoxicity, formation of immune
complexes leading to improved clear-
ance, and direct inhibition of virion infec-
tivity/cell-cell virus transfer by neutraliza-
tion. The authors further show that this
effect is greatly reduced in mice receiving
antibodies that are missing their Fc por-
tions, suggesting that Fc receptors are
involved in the process.
Nonetheless, when bNAbswere admin-
istered at 2–3 weeks post infection, after
persistent reservoirs are already estab-
lished, viral loads are suppressed to unde-
tectable levels but eventually rebound as
antibody concentrations wane, suggest-
ing that underlying viral reservoirs remain.
One potential strategy for purging latent
HIV reservoirs is to induce virus expres-
sion, which might allow killing of the host
cell by viral cytopathic effects or by the im-
mune response against the virus. This is
sometimes referred to as an ‘‘activation-
elimination’’ or ‘‘kick and kill’’ approach
to reservoir purging and would ideally be
performed under continuous ART to
prevent newly expressed virus from
spreading to additional host cells. This
approach could be augmented by the in-
clusion of agents that can recognize and8, August 28, 2014 ª2014 Elsevier Inc. 971
Figure 1. HIV Reservoir Reduction in Humanized Mice Using
Latency Activators and bNAbsspecifically kill the newly ex-
pressing cells, such as anti-
HIV Env immunotoxins or
genetically engineered HIV-
specific cytotoxic T lympho-
cytes (Marsden and Zack,
2013).
To try to flush out virus from
persistent reservoirs, the au-
thors then tested several la-
tency-reversing agents (LRAs)
individually along with the
antibody therapy, including
the histone deacetylase inhi-
bitor vorinostat, the BET bro-
modomain protein inhibitor
I-BET 151, and the immune
modulatory anti-CTLA4 anti-
body. These individual LRAs
do not significantly affect
rebound. However, when all
three LRAs are administered
together in conjunction with
the bNAbs, a significant
reduction in the number of
mice showing plasma virusrebound is achieved. It therefore appears
that the combination of latency-reversing
agents is able to upregulate HIV expres-
sion in reservoir cells to a sufficient level
for them to be eliminated by the bNAbs
(Figure 1). The ‘‘reservoir cells’’ in this
case may be truly latently infected cells
expressing no viral proteins or persis-
tently infected cells expressing viral
proteins below the threshold needed for
clearance by bNAbs. Therefore, in this
system, the bNAbs appear to function in
place of ART to suppress viral loads
and inhibit virus spread from latently
infected cells following activation, and
also as agents that aid in the clearance
of productively infected cells and free
virions induced by efficient virus
reactivation.
This study shows the potential for using
bNAbs for HIV reservoir clearance. The
observation that a reduction in plasma972 Cell 158, August 28, 2014 ª2014 Elsevievirus rebound only occurs when a combi-
nation of different LRAs is used reinforces
a growing appreciation in the field
that synergistic activation achieved by
multiple activating agents that operate
via different pathways is likely to provide
more complete and robust virus acti-
vation in vivo than individual agents
used in isolation. As better activators of
latent virus are identified, the reservoir
clearance achieved with this type of
approach might be further improved.
More generally, this study provides an
important proof of concept that HIV
reservoirs can be impacted in a relevant
in vivo system using activation-elimina-
tion approaches, which can in turn pro-
duce the clinically relevant outcome of a
delay in viral rebound. These data also
strengthen the case for the inclusion of
anti-HIV antibody approaches such as
passive immunization, therapeutic vacci-r Inc.nation to elicit B cell re-
sponses, or gene therapy us-
ing vectors encoding broadly
neutralizing antibodies (Ba-
lazs et al., 2012) in future HIV
cure strategies.
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